AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Lifecare ASA

Share Issue/Capital Change Oct 18, 2024

3654_rns_2024-10-18_068371ae-7bc1-4685-ac5d-fdb915993bfb.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Lifecare ASA: Share capital increase registered

Lifecare ASA: Share capital increase registered

Reference is made to the stock exchange announcement made by Lifecare ASA (the

"Company") on 15 October 2024 regarding the successful results of the retail

offering (the "Offering") of 831,266 new shares (the "Offer shares") in the

Company, raising gross proceeds of NOK 16.6 million.

The share capital increase pertaining to the issuance of the new shares in the

Offering has now been registered with the Norwegian Register of Business

Enterprises. The Company's new share capital is NOK 82,435,490.80 divided into

15,852,979 shares, each with a nominal value of NOK 5.20.

The Offer Shares are expected to be delivered to applicants in the VPS on or

about 22 October 2024, subject to timely payment having been received. The

Offer Shares will be tradable following delivery of the Offer Shares to

applicants in the VPS, expected on or about 22 October 2024. The Company's

shares, including the Offer Shares, are expected to become tradable on Oslo

Børs on or about 22 October 2024.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-10-18 10:59 CEST.

Talk to a Data Expert

Have a question? We'll get back to you promptly.